<img src="https://ml.globenewswire.com/Resource/Download/6ddb04fb-e5ac-416b-b90b-b4cbf51dc538?size=2" nborder="0" align="left" hspace="5" vspace="5" title="blue_logo_stacked.jpg" alt="Tempest Therapeutics"/>BRISBANE, Calif., Sept. 08, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company pioneering the development of advanced in vivo CAR-T therapies for cancer and autoimmune disease, today announced that Matt Angel, Ph.D., Tempest’s President and Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026 at 2:30 p.m. ET. The webcast will be posted to Tempest’s website at <a href="https://www.globenewswire.com/Tracker?data=7yCmMZqgoneC_TyaxhjobIMAYnJ116WUUduN9VbT1RYFVtkvY8n-b-EL48cmFPPwYalNrBiznY9bOnpHFf_o63E_5FWE0JvyI5iJqSEGixo=" rel="nofollow" target="_blank" title="">https://ir.tempesttx.com</a> and will be archived for two weeks following the presentation. About Tempest Therapeutics Tempest is a clinical-stage biotechnology company developing next-generation in vivo CAR-T therapies for cancer and autoimmune disease. Tempest’s lead product candidate, TPST-4003, combines a clinically supported dual-targeting CD19/BCMA CAR structure with an advanced CD7-targeting delivery system to support broad immune reset across multiple indications. Tempest envisions a world in which immune reset therapies bring safe, effective, and broadly accessible therapeutic options to patients in need. For additional information, visit Tempest’s website at <a href="https://www.globenewswire.com/Tracker?data=7yCmMZqgoneC_TyaxhjobG04z6biC-TfUAqLy1mz8BwwPleNp2jzZp2wG-ledkYWmTwScuwh_aSGMHXlEBpIdUr8arBMj7s83FXly1OwyfQ=" rel="nofollow" target="_blank" title="">https://www.tempesttx.com</a>. Forward-Looking Statements This press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, concerning Tempest. These statements may discuss goals, intentions, and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Tempest, as well as assumptions made by, and information currently available to, management of Tempest. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “could”, “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “goal”, “suggest”, “target” and other similar expressions. All statements that are not historical facts are forward-looking statements, including but not limited to, statements regarding: Tempest’s plan to present at the H.C. Wainwright 28th Annual Global Investment Conference. All forward-looking statements in this press release are based on Tempest’s current expectations, estimates and projections about its industry as well as management’s current beliefs and expectations of future events only as of today and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to Tempest’s need for additional capital to fund its planned programs and operations and to continue to operate as a going concern; unexpected safety or efficacy data observed during preclinical or clinical trials; the possibility that results from prior clinical trials and preclinical studies may not necessarily be predictive of future results; past results may not be indicative of future results; clinical trial site activation or enrollment rates that are lower than expected; loss of key personnel; changes in expected or existing competition; changes in the regulatory environment; risks relating to volatility and uncertainty in the capital markets for biotechnology companies; and unexpected litigation or other disputes. These and other factors that may cause actual results to differ from those expressed or implied are discussed in greater detail in the “Risk Factors” section of Tempest's Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 30, 2026, and in other documents filed by Tempest from time to time with the SEC. Except as required by applicable law, Tempest undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Tempest’s views as of any date subsequent to the date of this press release and should not be relied upon as prediction of future events. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Tempest. Investor Contacts: Sylvia Wheeler Wheelhouse Life Science Advisors swheeler@wheelhouselsa.com Aljanae Reynolds Wheelhouse Life Science Advisors areynolds@wheelhouselsa.com <img alt="" src='https://ml.globenewswire.com/media/M2VlODkzNTktNzJmZi00NmU2LWEzNDMtMzExNGY1NGFjNjllLTEyMDE0ODctMjAyNi0wOS0wOC1lbg==/tiny/Tempest-Therapeutics.png' referrerpolicy='no-referrer-when-downgrade' />

Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn